Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)

Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune...

Full description

Saved in:
Bibliographic Details
Published in:Zhongguo fei ai za zhi 2021-04, Vol.24 (4), p.217-235
Main Authors: Zhou, Caicun, Wang, Jie, Wang, Baocheng, Cheng, Ying, Wang, Zhehai, Han, Baohui, Lu, You, Wu, Gang, Zhang, Li, Song, Yong, Zhu, Bo, Hu, Yi, Wang, Ziping, Song, Qibin, Ren, Shengxiang, He, Yayi, Hu, Xiaohua, Zhang, Jian, Yao, Yu, Zhao, Hongyun, Wang, Zhijie, Chu, Qian, Duan, Jianchun, Liu, Jingjing, Qin, Shukui
Format: Article
Language:Chinese
Subjects:
Antigens
Antineoplastic Agents, Immunological - administration & dosage
B7-H1 Antigen - administration & dosage
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Chemotherapy
China
Consensus
Cytotoxicity
expert consensus
Humans
Immune Checkpoint Inhibitors - administration & dosage
Immunotherapy
Lung cancer
lung neoplasms
Lung Neoplasms - drug therapy
Lymphocytes
Metastasis
Mortality
Oncology
Programmed Cell Death 1 Receptor - administration & dosage
programmed cell death protein 1/programmed death-ligand 1
T cell receptors
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune checkpoint inhibitors (ICIs), especially targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of NSCLC. ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) translocation in the first- or second-line setting, and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising in adjuvant/neoadjuvant therapy. More and more ICIs have been approved domestically for the treatment of NSCLC. Led by the NSCLC expert committee of Chinese Society of Clinical Oncology (CSCO), this consensus was developed and updated based on th
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2021.101.13